Cytoreductive Surgery Plus Hyperthermic Perioperative Chemotherapy for Selected Patients with Peritoneal Metastases from Colorectal Cancer: A New Standard of Care or an Experimental Approach?

Peritoneal metastases (PM) are a common presentation for patients with metastatic colorectal cancer (CRC), and the median survival of patients with PM is approximately one year. In a majority of patients, the disease remains limited to the peritoneal cavity. Therefore, investigators have applied cyt...

Full description

Saved in:
Bibliographic Details
Main Author: Paul H. Sugarbaker
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2012/309417
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849404588584599552
author Paul H. Sugarbaker
author_facet Paul H. Sugarbaker
author_sort Paul H. Sugarbaker
collection DOAJ
description Peritoneal metastases (PM) are a common presentation for patients with metastatic colorectal cancer (CRC), and the median survival of patients with PM is approximately one year. In a majority of patients, the disease remains limited to the peritoneal cavity. Therefore, investigators have applied cytoreductive surgery (CRS) and heated perioperative chemotherapy (HIPEC) as a standard approach for selected patients with PM from CRC. These investigators have demonstrated a very promising long-term survival in a subset of patients with a limited amount of isolated peritoneal metastatic disease. This paper presents the data that supports CRS and HIPEC as a treatment option for CRC patients with PM. These results of treatment are compared and contrasted to the results that can be expected with systemic chemotherapy alone.
format Article
id doaj-art-9afd2a59ff1246ddbc806d35e41a0a1c
institution Kabale University
issn 1687-6121
1687-630X
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Gastroenterology Research and Practice
spelling doaj-art-9afd2a59ff1246ddbc806d35e41a0a1c2025-08-20T03:36:57ZengWileyGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/309417309417Cytoreductive Surgery Plus Hyperthermic Perioperative Chemotherapy for Selected Patients with Peritoneal Metastases from Colorectal Cancer: A New Standard of Care or an Experimental Approach?Paul H. Sugarbaker0Washington Cancer Institute, Program in Peritoneal Surface Malignancy, Washington, DC 20010, USAPeritoneal metastases (PM) are a common presentation for patients with metastatic colorectal cancer (CRC), and the median survival of patients with PM is approximately one year. In a majority of patients, the disease remains limited to the peritoneal cavity. Therefore, investigators have applied cytoreductive surgery (CRS) and heated perioperative chemotherapy (HIPEC) as a standard approach for selected patients with PM from CRC. These investigators have demonstrated a very promising long-term survival in a subset of patients with a limited amount of isolated peritoneal metastatic disease. This paper presents the data that supports CRS and HIPEC as a treatment option for CRC patients with PM. These results of treatment are compared and contrasted to the results that can be expected with systemic chemotherapy alone.http://dx.doi.org/10.1155/2012/309417
spellingShingle Paul H. Sugarbaker
Cytoreductive Surgery Plus Hyperthermic Perioperative Chemotherapy for Selected Patients with Peritoneal Metastases from Colorectal Cancer: A New Standard of Care or an Experimental Approach?
Gastroenterology Research and Practice
title Cytoreductive Surgery Plus Hyperthermic Perioperative Chemotherapy for Selected Patients with Peritoneal Metastases from Colorectal Cancer: A New Standard of Care or an Experimental Approach?
title_full Cytoreductive Surgery Plus Hyperthermic Perioperative Chemotherapy for Selected Patients with Peritoneal Metastases from Colorectal Cancer: A New Standard of Care or an Experimental Approach?
title_fullStr Cytoreductive Surgery Plus Hyperthermic Perioperative Chemotherapy for Selected Patients with Peritoneal Metastases from Colorectal Cancer: A New Standard of Care or an Experimental Approach?
title_full_unstemmed Cytoreductive Surgery Plus Hyperthermic Perioperative Chemotherapy for Selected Patients with Peritoneal Metastases from Colorectal Cancer: A New Standard of Care or an Experimental Approach?
title_short Cytoreductive Surgery Plus Hyperthermic Perioperative Chemotherapy for Selected Patients with Peritoneal Metastases from Colorectal Cancer: A New Standard of Care or an Experimental Approach?
title_sort cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer a new standard of care or an experimental approach
url http://dx.doi.org/10.1155/2012/309417
work_keys_str_mv AT paulhsugarbaker cytoreductivesurgeryplushyperthermicperioperativechemotherapyforselectedpatientswithperitonealmetastasesfromcolorectalcanceranewstandardofcareoranexperimentalapproach